^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    CANCER:

    Clear Cell Renal Cell Carcinoma

    Related cancers:
    2d
    Telomere-based Risk Model for Prognosis Prediction in Clear Cell Renal Cell Carcinoma. (PubMed, Curr Med Chem)
    This study identified six telomere-related genes with high expression and strong diagnostic value in ccRCC, highlighting their association with immune infiltration and potential as diagnostic and therapeutic targets.
    Journal
    |
    MELK (Maternal Embryonic Leucine Zipper Kinase) • BUB1 (BUB1 Mitotic Checkpoint Serine/Threonine Kinase) • CEP55 (Centrosomal Protein 55)
    2d
    Memory-like Natural Killer (NK) Cell Therapy in Patients With Renal Cell Carcinoma or Urothelial Carcinoma (clinicaltrials.gov)
    P1, N=10, Recruiting, Dana-Farber Cancer Institute | Trial completion date: May 2030 --> Jul 2031 | Trial primary completion date: Dec 2025 --> Feb 2027
    Trial completion date • Trial primary completion date
    |
    PD-L1 (Programmed death ligand 1) • PD-1 (Programmed cell death 1)
    |
    CIML NK
    3d
    ACACA modulates R-loop homeostasis to enhance lipid metabolism and microenvironmental interactions in ccRCC. (PubMed, NPJ Precis Oncol)
    In vitro and xenograft experiments further demonstrated that ACACA promoted proliferation and migration and suppressed apoptosis, accompanied by reduced R-loop accumulation, enhanced fatty acid metabolism and improved mitochondrial function. Together, these findings identify ACACA as an R-loop-associated metabolic driver connecting genomic stress with lipid reprogramming and TME remodeling in ccRCC, supporting its potential as a prognostic biomarker and therapeutic target.
    Journal
    |
    ACACA (Acetyl-CoA Carboxylase Alpha)
    3d
    A single-arm, single-center clinical study of toripalimab as adjuvant therapy for high-risk clear cell renal cell carcinoma after radical nephrectomy (ChiCTR2500115679)
    P=N/A, N=100, Not yet recruiting, The First Affiliated Hospital of Xi'an Jiaotong University; The First Affiliated Hospital of Xi'an Jiaotong University
    New trial
    |
    Loqtorzi (toripalimab-tpzi) • Imjudo (tremelimumab-actl)
    3d
    An observational study on the use of circulating tumor DNA for postoperative prognosis assessment and recurrence monitoring in clear cell renal cell carcinoma (ChiCTR2500114029)
    P=N/A, N=50, Not yet recruiting, Chinese PLA General Hospital; Chinese PLA General Hospital
    New trial
    3d
    Toripalimab Combined with Lenvatinib for Postoperative Adjuvant Therapy in Non-Clear Cell Renal Cell Carcinoma with High Recurrence Risk: An Evaluation of Efficacy and Safety (ChiCTR2500113091)
    P=N/A, N=60, Not yet recruiting, The Third Medical Centre, Chinese PLA General Hospital; The Third Medical Centre, Chinese PLA General Hospital
    New trial
    |
    SMARCB1 (SWI/SNF Related, Matrix Associated, Actin Dependent Regulator Of Chromatin, Subfamily B, Member 1) • FH (Fumarate Hydratase) • TFE3 (Transcription Factor Binding To IGHM Enhancer 3) • TFEB (Transcription Factor EB 2)
    |
    Lenvima (lenvatinib) • Loqtorzi (toripalimab-tpzi)
    3d
    Molecular Subtyping of Advanced Clear Cell Renal Cell Carcinoma Treated with Axitinib Plus Toripalimab: A Biomarker Exploratory Analysis Based on the Phase III RENOTORCH Trial (ChiCTR2500112859)
    P=N/A, N=210, Not yet recruiting, The Third Medical Centre, Chinese PLA General Hospital, Beijing, China; Chinese PLA General Hospital
    New trial
    |
    Loqtorzi (toripalimab-tpzi) • axitinib
    3d
    A Study Protocol (RENOFIRE-01) on the Preoperative Use of Axitinib + Toripalimab + Selective Tumor Embolization +/- Cytoreductive Nephrectomy in Oligometastatic Renal Cell Carcinoma (ChiCTR2500112304)
    P=N/A, N=52, Recruiting, Tianjin Cancer Hospital Airport Hospita; Tianjin Cancer Hospital Airport Hospita
    New trial
    |
    Loqtorzi (toripalimab-tpzi) • axitinib
    3d
    A Single-Arm, Single-Center Clinical Study of Vorolanib Combined with Toripalimab as First-Line Therapy for Metastatic Clear Cell Renal Cell Carcinoma (ChiCTR2500111737)
    P4, N=30, Not yet recruiting, The First Affiliated Hospital of Xi'an Jiaotong University; The First Affiliated Hospital of Xi'an Jiaotong University
    New P4 trial
    |
    Loqtorzi (toripalimab-tpzi) • Fumena (vorolanib)
    3d
    The efficacy and safety of Iparomlimab and Tuvonralimab (QL1706) combined with Lenvatinib as neoadjuvant therapy in renal cancer with partial nephrectomy indications but high surgical risk：A single arm, Phase II clinical study (ChiCTR2500111466)
    P2, N=25, Not yet recruiting, Sun Yat-sen University Cancer Center; Sun Yat-sen University Cancer Center
    New P2 trial
    |
    Lenvima (lenvatinib) • Qibeian (iparomlimab/tuvonralimab) • iparomlimab (QL1604)
    5d
    miR-301b-3p/ITPKB drives clear cell renal cell carcinoma progression by promoting PARP1/IL8-mediated neutrophil extracellular trap formation. (PubMed, Int J Biol Macromol)
    These NETs facilitate tumor cell migration and adhesion while conferring resistance to tyrosine kinase inhibitors (sunitinib and sorafenib) and anti-PD-1 therapy. In vivo, the treatment with DNase1 to disrupt NETs effectively reversed this therapeutic resistance. Our findings unveil the miR-301b-3p/ITPKB/PARP1/IL8/NETs axis as a novel mechanistic link between tumor-intrinsic signaling and neutrophil-driven immunosuppression, providing a solid experimental foundation for developing combination therapeutic strategies for advanced ccRCC.
    Journal
    |
    CXCL8 (Chemokine (C-X-C motif) ligand 8) • PARP1 (Poly(ADP-Ribose) Polymerase 1)
    |
    sorafenib • sunitinib
    5d
    GCAR1, a Chimeric Antigen Receptor (CAR) T-CELL Therapy for Relapsed/Refractory GPNMB-Expressing Solid Tumours (clinicaltrials.gov)
    P1, N=30, Not yet recruiting, Canadian Cancer Trials Group | Trial completion date: Jun 2029 --> Sep 2033
    Trial completion date
    |
    HER-2 (Human epidermal growth factor receptor 2) • PD-L1 (Programmed death ligand 1) • PGR (Progesterone receptor) • GPNMB (Glycoprotein Nmb)
    |
    PD-L1 expression • HER-2 negative
    |
    cyclophosphamide • fludarabine IV